Cryosite
- Short interest
- 0.00%
- as of 23 May 2025
- Reported shorts
- 634
- Shares on issue
- 48.810M
Cryosite (CTE) Short Interest
Cryosite (ASX:CTE) had 0.00% of shares reported as short positions as of 23 May 2025, representing 634 shares. Cryosite operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Cryosite
Cryosite Ltd is an Australian company specializing in outsourced clinical trials logistics, biological storage, and sample management services. They provide integrated solutions, including the storage of cord blood stem cells for private use, and manage clinical supply chain activities with expertise in temperature-sensitive products.
Company profile →Cryosite (ASX:CTE) has 0.00% of its shares on issue reported as short positions as of 23 May 2025, or about 634 shares. CTE is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads CTE today
- Zanger BreakoutWatchScore 15rank 1506 of 1942
- CAN SLIMWatchScore 15rank 902 of 1541
- Minervini Trend TemplateWatchScore 53rank 268 of 1716
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 63rank 56 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
CTE fundamentals
In the year to 30 Jun 2026, Cryosite (ASX:CTE) recorded revenue of A$16.7M and net profit after tax of A$2.2M. A year earlier it recorded revenue of A$14.1M and net profit after tax of A$1.9M. Year-on-year growth: revenue +18.3% (FY), EPS +14.8% (TTM). Net margin 13.4%, return on equity 61.7% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest CTE news
All news- 2026 AGM Notice of Meeting, Letter of Access and Proxy
asx · 20 Sept 2026
- Cryosite ASX:CTE) Falls Into the Red - What Investors Should Watch Next? - Kalkine
googlenews · 11 Sept 2026
- CTE study finds 70pc of head impacts happening in sports practice
abc · 25 Aug 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss CTE
Start a research thread or post the first pulse update